MHRA Drug Safety Update — topical steroidsPeacock, DianeBritish Journal of General Practice
Implementing drug safety updatesImplementing drug safety updatesIn August 2007, the Medicines and Healthcare products Regulatory Agency (MHRA) launched its monthly Drug Safety Update.1 As would be expected from a publication produced by the MHRA, it is based on robust analysis of pharmacovigilance dat...
Comment on the recent Drug Safety Update for August 2008 published by the Medicines and Healthcare products Regulatory Agency (MHRA)doi:10.1136/bmj.331.7515.498mediastinal tumorsschwannomaphrenic nerveclear cell chondrosarcomaWhile John Starr was working as a senior registrar at the Hammersmit...
Evaluating the communication within fire and rescue services and the NHS on the fire risk of emollients in accordance of the MHRA safety update The Medicines and Healthcare products Regulatory Agency update in 2018 reported 50 fatal fires linked with emollient use. It detailed the fire risk and ...
The April 2010 MHRA Drug Safety Update article above, however, suggest that the drug company will not be permitted to essentially tell doctors and patients that those two medical articles -- which are among the most recent additions to the medical literature about the safety of YAZ and Yasmin ...
The Yellow Card Scheme is used by the Medicines and Healthcare products Regulatory Agency (MHRA) to monitor the safety of currently licensed medicines and vaccines in the UK and is part of routine pharmacovigilance. Currently, health professionals (doctors, dentists, nurses, and pharmacists), corone...
As we are focusing in this article on the fact that Xeljanz increases infection risks, we limit our review to that aspect of the MHRA XeljanzDrug Safety Updatereport. In relevant part, here is what is being pointed out: [Xeljanz (tofacitinib)] is known to increase the risk of serious and...
MHRA | UK Michael Bean Johnson & Johnson Michael Von Forstner Sobi | Switzerland Mateja Pranjić GSK | UK VIEW ALL SPEAKERS To Speak At PV Europe CongressClick Here International Companies Attending PV Europe WHO SHOULD ATTEND Pharmacovigilance Europe Congress attracts senior level attendees from lead...
The results proved the assumption on safety of low-dose quinidine therapy. Antihistamines Terfenadine and astemizole were the first second-generation, non-sedating antihistamines. When launched to the market they were considered as a great breakthrough in the allergy pharmacotherapy. However, ...
Owing to their specificity, immunomodulatory biologics generally have better safety profiles than small-molecule drugs. However, adverse effects such as an increased risk of infections or cytokine release syndrome are of concern. Here, Park and colleague